Covert Hepatic Encephalopathy Is a Multi-Organ Crisis Most Cirrhosis Patients Never Know They Have

Millions of people living with liver cirrhosis carry a hidden neurological burden they cannot name or feel clearly. Subtle memory lapses, slowed reaction times, and impaired driving ability accumulate quietly while standard clinical visits miss the diagnosis entirely. A comprehensive review published in the Journal of Gastroenterology by Takao Miwa, Cynthia L. Hsu, Masahito Shimizu, Patricia P. Bloom, and Bernd Schnabl at the University of California San Diego reframes covert hepatic encephalopathy (CHE) not as a brain problem sitting in isolation but as a whole-body crisis demanding rethinking of how cirrhosis care is organized.

Covert Hepatic Encephalopathy Silently Raises Mortality Risk in Cirrhosis Patients

CHE is a highly prevalent complication of liver cirrhosis. Unlike overt hepatic encephalopathy, which produces visible confusion or stupor, CHE operates beneath the threshold of obvious clinical signs, affecting cognition, attention, and quality of life in ways patients often attribute to fatigue or aging. Despite its prevalence, it significantly increases the risk of progressing to overt hepatic encephalopathy and raises overall mortality. The review's central argument is that CHE should be understood as a multi-organ syndrome involving complex, bidirectional crosstalk among the liver, gut, skeletal muscle, kidneys, and brain. Viewing it through any single organ lens, the authors argue, is part of why it remains so consistently underdiagnosed and undertreated in real-world clinical practice. Just as patient-reported outcomes in gastroenterology often reveal a disease burden that traditional biomarkers miss entirely, CHE's impact on daily life runs well ahead of what a standard liver panel can detect.

How Ammonia, Gut Dysbiosis, and Sarcopenia Converge to Drive CHE

The pathophysiology the review outlines is intricate but follows a coherent logic. Impaired ammonia handling sits at the center. The cirrhotic liver loses its capacity to convert ammonia into urea efficiently, allowing ammonia to accumulate in the bloodstream. Once in the brain, that hyperammonemia induces astrocytic dysfunction, brain edema, and neuroinflammation; astrocytes, the brain's primary support cells, swell and malfunction under ammonia load, disrupting neurotransmission and cognitive performance.

But ammonia alone does not explain the full picture. Systemic inflammation, oxidative stress, gut dysbiosis, and altered microbial metabolites including bile acids and short-chain fatty acids all modulate how severely CHE expresses itself in any given patient. Sarcopenia, the progressive loss of skeletal muscle mass common in advanced cirrhosis, worsens outcomes by removing a major site of extrahepatic ammonia clearance: healthy muscle metabolizes ammonia, and when that muscle is gone, ammonia loads rise further. The gut microbiome's composition shapes how much ammonia is produced in the first place, and altered bile acid profiles from a dysbiotic gut feed back into hepatic inflammation. This interconnected web is what the authors call the gut-liver-muscle-brain axis, and it is why a gastroenterologist, a hepatologist, a neuropsychologist, a physiotherapist, and a dietitian all have legitimate stakes in a single patient's care. The gut microbiota's broad role in disease and health has been documented across multiple gastrointestinal conditions, but CHE may represent one of its most clinically underappreciated expressions.

Stroop Tests and Psychometric Batteries Catch What Routine Visits Miss

Diagnosing CHE requires stepping outside the standard clinical encounter. The review catalogues two main diagnostic approaches: psychometric test batteries and point-of-care tools. Psychometric batteries assess multiple cognitive domains including attention, processing speed, and working memory, and have been validated in cirrhotic populations. Point-of-care tools are faster and more practical for busy hepatology clinics; the Stroop test, which measures interference between color naming and word reading, and the animal naming test, which evaluates verbal fluency, both offer rapid, validated windows into cognitive function without specialized equipment.

Clinical guidelines already recommend screening for CHE in patients with cirrhosis, which makes the real-world gap the authors identify especially striking. Diagnostic and therapeutic algorithms exist on paper but are not fully implemented in practice. Many patients with CHE remain undiagnosed and untreated despite those guidelines. The barriers are practical: time pressure in clinics, limited awareness of point-of-care tools, and uncertainty about when treatment changes outcomes enough to justify the screening effort. The review argues that understanding CHE's natural history is essential not only for catching the diagnosis but for counseling patients appropriately about prognosis and treatment decisions. This implementation gap parallels broader unmet needs in gastrointestinal disease research, where new evidence consistently outpaces clinical adoption.

Therapeutic Strategies Span Diet, Microbiome Modulation, and Ammonia Reduction

Treatment for CHE is not a single drug but a portfolio of interventions targeting different nodes in the gut-liver-muscle-brain axis. Lactulose and rifaximin are the most established pharmacological tools: lactulose acidifies the colon to trap ammonia and speed its excretion, while rifaximin, a minimally absorbed antibiotic, reduces the ammonia-producing bacterial populations in the gut. Branched-chain amino acids address the sarcopenia dimension by providing substrates for muscle protein synthesis and serving as an alternative ammonia disposal route.

Dietary protein management has also evolved. Earlier dogma restricted protein intake in encephalopathic patients, but current evidence supports adequate protein, particularly from plant and dairy sources that generate less ammonia during digestion than meat proteins do. Microbiome-directed interventions including prebiotics and probiotics remain active areas of investigation, consistent with the field's growing interest in modulating gut ecology for systemic benefit. The authors emphasize multidisciplinary care as a structural necessity rather than a preference: nutrition, physical rehabilitation for sarcopenia, cognitive monitoring, and pharmacotherapy need to be coordinated rather than sequenced.

Closing the Gap Between CHE Guidelines and Real-World Cirrhosis Care

The review by Miwa and colleagues lands at a moment when the tools to close the diagnostic gap are already available. Point-of-care tests like the Stroop test require no specialized equipment and take minutes. Validated psychometric batteries can be administered by trained nurses. Rifaximin and lactulose are widely accessible. What is missing is not evidence but implementation: systematic screening protocols embedded in hepatology workflows, multidisciplinary team structures that bring dietitians and physiotherapists into cirrhosis clinics, and patient education that helps people recognize subtle cognitive changes as liver-related rather than incidental. The authors frame CHE not as a niche complication but as a treatable syndrome that, when caught early, can meaningfully reduce the trajectory toward overt encephalopathy, hospitalization, and death. For the substantial proportion of cirrhosis patients silently carrying this diagnosis, that framing could translate into earlier intervention and better years.